The IC-SOHO study was designed to supply information on antipsychotic treatments in the real clinical practice by assessment of a large and diverse sample population with @entity161 . This document describes the findings of the first 6 months of IC-SOHO in Latin America. To date, this is the largest observational study of its type in this region. In this observational and prospective study, those out- @entity1 with @entity161 , who require a change or initiation of antipsychotic medication are hospitalized. Effectiveness was evaluated using the Clinical Global Impression-Seriousness (CGI-S) grading scale. Tolerability was assessed by questionnaires on adverse events and weight measurements. Herein, the comparisons between @entity1037 (monotherapy), @entity1090 (monotherapy) and conventional antipsychotics (monotherapy and combined therapy) are presented. As a whole, 7,658 @entity1 participated in the ICSOHO; n=2,671 from 11 countries of Latin America that were included in this report. At 6 months, the proportion of @entity1 who responded to @entity1037 was significantly greater than those who responded to @entity1090 or conventional antipsychotics (p<0.001). @entity1 from the @entity1037 group had greater improvements in all the symptom domains, including general, positive, negative, @entity308 in comparison with @entity1090 (p<0.05) or conventional antipsychotics (p < 0.001). @entity21 ( @entity21 ) and @entity910 ( @entity910 ) decreased from baseline in the groups treated with @entity1037 and @entity1090 , but increased in the conventional group. The adverse events related with the sexual function were more prominent in the conventional group. Weight gain was observed in each treatment group, although the @entity1 from the @entity1037 group had greater weight grain followed by those of @entity1090 and then by those of conventional antipsychotics. Our findings in this population of the Latin American sample emulate the results of other studies in different samples, where it was found that @entity1037 was more effective and better tolerated than @entity1090 or conventional antipsychotics.

[The intercontinental XXXX outpatient health outcomes study (IC-SOHO): initial 6 month findings of the sample in Latin America].

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity308 :: ('MESH:D003866', 'Disease') :: ['depressive and cognitive symptoms'] @entity910 :: ('MESH:D004409', 'Disease') :: ['TD', 'tardive dyskinesia'] @entity161 :: ('MESH:D012559', 'Disease') :: ['schizophrenia'] @entity21 :: ('MESH:D001480', 'Disease') :: ['Extrapyramidal symptoms', 'EPS'] @entity1037 :: ('MESH:C076029', 'Chemical') :: ['olanzapine'] @entity1090 :: ('MESH:D018967', 'Chemical') :: ['risperidone']
@entity161 :: (MESH:D012559,Disease) :: ['schizophrenia']
